Please select the eligibility criteria that correspond to the clinical trial below.
Title: Transcutaneous Electrical Acupoint P6 Stimulation vs. Tropisetron Both in Combination With Dexamethasone to Prevent Postoperation Nausea and Vomiting in Women
Brief Summary: The purpose of this study is to access the effect of TEAS of P6 in the prevention of PONV in women scheduled for gynecologic laparoscopic surgery with general anesthesia.


Options:
A: Inclusion Criteria:

* patients undergoing thyroid surgery

Exclusion Criteria:

* ASA physical class III or IV
* age \> 75 years
* pregnancy
B: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I or II
* aged between 18 to 60yr
* scheduled for elective gynecological laparoscopic surgery requiring general anesthesia

Exclusion Criteria:

* pregnancy or breastfeeding
* mental retardation
* psychiatric or neurological disease
* use of antiemetics, emetogenic drugs, opioids or glucocorticosteroids within 3 days prior to surgery
* known allergy to tropisetron or dexamethasone
* nausea and/or vomiting within 24 hr prior to surgery
* implantation of a cardiac pacemaker, cardioverter, or defibrillator
* any skin problem at the acupoint stimulation area
C: Inclusion Criteria:

* Arthroscopic subacromial decompression and/or acromioclavicular resection
* General anaesthesia
* Daysurgery, Horsens Hospital

Exclusion Criteria:

* Incompetent
* Pregnant
* Age under 18 or over 90 years
* Allergy toward dexamethasone
* Diabetes
* Active gastric ulcer
* Untreated hypertension
* Glaucoma
* Daily use of glucocorticoids or strong opioids
* Daily use of analgesics for unrelated illness
* Myasthenia gravis
* Mitochondrial disorders
D: Inclusion Criteria:

* Male or female patients ≥ 18 years of age
* Written informed consent
* Patients undergoing elective surgery under general anaesthesia requiring at least one overnight stay in hospital for either:

  1. Hysterectomy (any surgical technique)
  2. Cholecystectomy (any surgical technique)
  3. Other elective surgery requiring overnight admission to hospital and scheduled to last at least 1 hour from induction of anaesthesia
* Patients with at least 2 risk factors for PONV, defined as 2 of the following:

  1. Past history of PONV and/or motion sickness
  2. Non-smoking status
  3. Female gender
  4. Planned opiate use for post-operative analgesia
* American Society of Anesthesiologists (ASA) risk score I-III (see Appendix 3)
* Adequate hepatic and renal function

  * Alanine aminotransferase (ALT) \<2.5 \* upper limit normal (ULN)
  * Aspartate aminotransferase (AST) \<2.5 \* ULN
  * Bilirubin \<1.5 \* ULN
  * Creatinine \<1.5 \* ULN
* Adequate haematological function

  * Haemoglobin ≥9.5 g/dL
  * White blood count 4.0-11.0 \* 10\^9/L
  * Platelet count ≥150 - 400 \* 10\^9/L
* Ability and willingness to give written informed consent

Exclusion Criteria:

* Patients undergoing outpatient/day case surgery
* Patients undergoing surgery where the patient is expected to remain ventilated for a period after surgery
* Patients undergoing intra-thoracic, transplant or central nervous system surgery
* Patients receiving a local anaesthetic/regional neuraxial (intrathecal or epidural) block
* Patients receiving monoamine oxidase inhibitor (MAOI) therapy currently or in the preceding 3 weeks
* Patients with a pre-existing vestibular disorder or history of dizziness
* Patients that are expected to need a naso- or oral-gastric tube in situ after surgery is completed
* Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study
* Patients treated with regular anti-emetic therapy including corticosteroids
* Patients receiving CYP3A4 inducers or inhibitors within 7 days prior to study including but not limited to erythromycin, itraconazole, nefazodone, diltiazem, verapamil, rifampicin
* Patients with pre-existing nausea or vomiting 24 hours before surgery
* Patients who are breast feeding or pregnant
* Patients with a history of alcohol abuse
* Patients diagnosed with Parkinson's disease
* Patients who have received anti-cancer chemotherapy in the previous 4 weeks
* Patients with pre-existing clinically significant cardiac arrhythmia
* Patients with a history of epilepsy
* Patients who have participated in a previous study within the last 28 days (French sites only: Patients who have participated in a previous study within the last 6 months, if required by national or local regulations)

Answer: B